Global Acinetobacter Infections Treatment Sales Market Report 2021

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.

Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.

Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.
In the last several years, global market of Acinetobacter Infections Treatment developed rapidly, with an average growth rate of 2.96%. In 2016, United States Market Size of Acinetobacter Infections Treatment is nearly 22 M USD. For developing product, there are 1 in Phase III, 1 in Phase Ⅱ, 4 in Phase 1 and 8 in Preclinical. The total investment for Acinetobacter Infections Treatmen Drugs developing is around 90 M USD.

Market Analysis and Insights: Global Acinetobacter Infections Treatment Market
The global Acinetobacter Infections Treatment market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Acinetobacter Infections Treatment Scope and Market Size
The global Acinetobacter Infections Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Acinetobacter Infections Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Sulbactam
Carbapenems
Aminoglycosides
Polymyxins
Tetracyclines
Others

Segment by Application
ETX2514
Nacubactam RG6080
Arenicin
VXD-001
Small Molecule Antibiotic
AR-401 mAB
LCB01-0371 (PO)
GN-4474
Antibacterial Antibody

The Acinetobacter Infections Treatment market is analysed and market size information is provided by regions (countries). Segment by Application, the Acinetobacter Infections Treatment market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Entasis Therapeutics
Roche
Adenium Biotech
Vaxdyn
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals